SUNNYVALE, Calif.–(BUSINESS WIRE)–Pelvalon, a medical device company focused on developing innovative solutions for women suffering from loss of bowel control, today announced activities at PFD Week taking place through October 17 at the Washington State Convention Center in Seattle. PFD Week is an expansion of the American Urogynecologic Society (AUGS) 36th Annual Scientific Meeting, and highlights the importance of education on pelvic floor disorders, which impact one in three women.
Loss of bowel control is a form of pelvic floor disorder. There is an increasing focus within pelvic health on loss the condition, since it is a prevalent condition with suboptimal treatments. Often called accidental bowel leakage (ABL) or fecal incontinence (FI), the condition can be caused by pregnancy, childbirth, nerve or muscle damage in the pelvic region, and irritable bowel syndrome (IBS) or other gastrointestinal conditions. More than 20 million U.S. women suffer from ABL.
At the meeting, data from the feasibility study of the company’s Eclipse™ System will be presented by Michelle Takase-Sanchez, M.D., of Ventura County Obstetric and Gynecologic Medical Group in Ventura, Calif.
Additionally, Eclipse will be a featured as part of a pre-conference workshop on accidental bowel leakage on October 14 with Catherine Matthews, M.D. of Wake Forest Baptist Medical Center; Dee Fenner, M.D. of University of Michigan Health System; Tristi Muir, M.D., of Houston Methodist Hospital; and Holly Richter, Ph.D, M.D., of the University of Alabama at Birmingham.
Pelvalon’s detailed schedule of activities at AUGS 2015 is as follows:
- Wednesday, October 14 – Pre-conference Workshop: 1:00 p.m. – 5:00 p.m., Room 609
An Evidenced-Based Approach to the Management of Accidental Bowel Leakage
Panel participants: Catherine Matthews, M.D.; Dee Fenner, M.D.; Tristi Muir, M.D.; Holly Richter, M.D.
- Friday, October 16 – General Scientific Session: 9:06 – 9:17 a.m., Hall 4A
A Staged Feasibility Study of a Novel Vaginal Bowel Control System for the Treatment of Fecal Incontinence in Adult Women
Presenter: Michelle Miki Takase-Sanchez
Pelvalon’s Eclipse System is a vaginal insert designed to offer women a non-surgical treatment for loss of bowel control. The insert is placed in the same location as a tampon or a diaphragm, and can be removed at any time. A hand-held pump is used to inflate and deflate a balloon on the insert. The balloon is designed to occlude the rectum to protect against unwanted stool passage. The insert does not contain drugs or hormones. The system was cleared by the FDA in February 2015 for the treatment of fecal incontinence in adult women.
Headquartered in Sunnyvale, California, privately held Pelvalon aims to improve the lives of women who suffer from bowel control problems. Founded in 2010, Pelvalon’s groundbreaking technology originated from Stanford University’s Biodesign program, a collaboration between the schools of medicine and engineering. Pelvalon’s investors include Norwich Ventures, a specialized venture capital firm focused on medtech.